Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ArriVent BioPharma, Inc. ( (AVBP) ) has provided an update.
On September 9, 2025, ArriVent BioPharma announced the final analysis of firmonertinib monotherapy data from its global Phase 1b study in EGFR PACC mutant non-small cell lung cancer at the World Conference on Lung Cancer. The study showed promising results, including a 16.0-month median progression-free survival and a 68.2% overall response rate in first-line patients. The data supports firmonertinib’s potential to address unmet needs in the EGFR mutant NSCLC treatment landscape, with plans to enroll the first patient in a Phase 3 trial in the second half of 2025.
The most recent analyst rating on (AVBP) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on ArriVent BioPharma, Inc. stock, see the AVBP Stock Forecast page.
Spark’s Take on AVBP Stock
According to Spark, TipRanks’ AI Analyst, AVBP is a Underperform.
The overall score reflects the high-risk, high-reward nature of an early-stage biotechnology company like ArriVent BioPharma. While the company shows strong balance sheet stability and strategic pipeline expansion, the lack of current revenue, negative cash flows, and recent downward price trends weigh heavily on the score. Investors should consider the potential long-term benefits of the oncology pipeline expansion balanced against the typical risks associated with biotech investments.
To see Spark’s full report on AVBP stock, click here.
More about ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics to meet unmet medical needs in cancer treatment. The company aims to leverage its expertise in drug development to advance its lead candidate, firmonertinib, and other novel therapeutics, including next-generation antibody drug conjugates, towards approval and commercialization.
Average Trading Volume: 343,696
Technical Sentiment Signal: Sell
Current Market Cap: $819.1M
See more data about AVBP stock on TipRanks’ Stock Analysis page.